Intercept Pharmaceuticals has submitted its top candidate to the FDA for approval in primary biliary cirrhosis, a rare disease that results in serious liver damage. …read more Source: Intercept files its ‘breakthrough’ liver drug for rare disease approval
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis. …read more Source: Transgene is shedding 120 jobs to save cash and get its pipeline moving
Biotech billionaire Patrick Soon-Shiong has already laid the foundation for a big IPO to help finance his low-profile oncology R&D player Conkwest. Now he’s moving closer to getting his high-profile personalized drug-finding company NantHealth on the market as well. …read more Source: Biotech billionaire Soon-Shiong plots a second IPO–this time for NantHealth
Sam Waksal, the once-jailed former CEO of ImClone, is again the subject of fraud accusations as a former associate says he bailed on an investment deal designed to circumvent his punishment and defaulted on a $15 million promise. …read more Source: Waksal’s post-prison startup runs into more fraud allegations
Celgene’s $1 billion front-loaded deal to buy into Juno’s CAR-T and TCR programs–$150 million upfront and $850 million for 10% of the company’s stock at more than double the going share price–instantly and predictably spurred a backlash among some of the top analysts in the industry over the frothy figures in play. …read more Source: […]
Celgene is paying about $1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $150 million upfront and paying $93 a share–a huge premium–to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies. […]
Egalet’s in-development pain pill met its goals in a study designed to prove its abuse-deterrence, beating out a rival treatment from Purdue Pharma as it heads toward an FDA filing. …read more Source: Egalet’s pain pill is tougher to abuse than Purdue’s morphine tablet, study shows
AMAG Pharmaceuticals has stepped in to buy Cord Blood Registry for $700 million, capturing about half of the privately stored cord blood units and taking a prominent position as supplier of stem cells to R&D groups. …read more Source: AMAG snags Cord Blood Registry for $700M
Samsung Bioepis, a joint venture between the South Korean conglomerate and Biogen, is planning a jump to the Nasdaq with eyes on raising cash to market cheaper copies of blockbuster biologics. …read more Source: Samsung and Biogen plot an IPO for their biosimilars JV
Merck posted another batch of promising Phase III data for Emend, its antivomiting drug for chemo patients. The pharma giant noted that in the study its NK1 receptor agonist scored a statistically significant complete response rate among patients getting a moderately emetogenic (or vomit-inducing) chemotherapy. Merck will now look to broaden its label for the […]
